CRISPR Current Valuation

CRSP
 Stock
  

USD 78.66  1.20  1.55%   

CRISPR Therapeutics AG fundamentals help investors to digest information that contributes to CRISPR Therapeutics' financial success or failures. It also enables traders to predict the movement of CRISPR Stock. The fundamental analysis module provides a way to measure CRISPR Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CRISPR Therapeutics stock.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  

CRISPR Current Valuation Analysis

CRISPR Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
 2021 2022 (projected)
Interest Expense9.26 M9.99 M
Gross Profit914.96 M987.2 M
Enterprise Value 
 = 
Market Cap + Debt 
-  
Cash 
More About Current Valuation | All Equity Analysis

Current CRISPR Therapeutics Current Valuation

    
  3.83 B  
Most of CRISPR Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CRISPR Therapeutics AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

CRISPR Current Valuation Driver Correlations

Understanding the fundamental principles of building solid financial models for CRISPR Therapeutics is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Current Valuation. Since CRISPR Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of CRISPR Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of CRISPR Therapeutics' interrelated accounts and indicators.

CRISPR Current Valuation Historical Pattern

Today, most investors in CRISPR Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various CRISPR Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of CRISPR Therapeutics current valuation as a starting point in their analysis.
   CRISPR Therapeutics Current Valuation   
Share
       Timeline  
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Compare to competition

In accordance with the recently published financial statements, CRISPR Therapeutics AG has a Current Valuation of 3.83 B. This is 73.33% lower than that of the Healthcare sector and 17.55% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 76.96% higher than that of the company.
CRISPR Therapeutics AG is the top company in current valuation category among related companies. After adjusting for long-term liabilities, total market size of Biotechnology industry is currently estimated at about 1.42 Trillion. CRISPR Therapeutics adds roughly 3.83 Billion in current valuation claiming only tiny portion of stocks in Biotechnology industry.

CRISPR Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of CRISPR Therapeutics from analyzing CRISPR Therapeutics' financial statements. These drivers represent accounts that assess CRISPR Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of CRISPR Therapeutics' important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Average Assets295.25 M433.88 M694.87 M1.34 B2.61 B2.81 B
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(63.58 M)(160.91 M)72.03 M(338.87 M)397.48 M428.86 M
Earnings Before Interest Taxes and Depreciation Amortization USD(63.58 M)(160.91 M)72.03 M(338.87 M)397.48 M428.86 M
Earnings before Tax(66.61 M)(164.43 M)67.31 M(348.06 M)379.53 M409.49 M
Average Equity194.94 M341.25 M569.7 M1.2 B2.33 B2.51 B
Enterprise Value706.46 M992.24 M2.77 B9.81 B4.98 B4.53 B
Free Cash Flow(77.91 M)(99.01 M)49.99 M(256.72 M)457.27 M493.37 M
Invested Capital13.58 M1.17 M113.14 M609.49 M1.92 B2.07 B
Invested Capital Average13.29 M5.81 M74.92 M295.1 M1.48 B1.6 B
Market Capitalization963.13 M1.48 B3.36 B10.82 B5.8 B5.29 B
Tangible Asset Value271 M488.73 M1.07 B1.83 B2.75 B2.97 B
Working Capital233.87 M438.65 M930.44 M1.62 B2.3 B2.48 B

CRISPR Fundamentals

About CRISPR Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze CRISPR Therapeutics AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CRISPR Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CRISPR Therapeutics AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats CRISPR-associated protein 9 platform. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland. CRISPR Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 473 people.

CRISPR Therapeutics Investors Sentiment

The influence of CRISPR Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in CRISPR. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Investor biases related to CRISPR Therapeutics' public news can be used to forecast risks associated with investment in CRISPR. The trend in average sentiment can be used to explain how an investor holding CRISPR can time the market purely based on public headlines and social activities around CRISPR Therapeutics AG. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
CRISPR Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for CRISPR Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average CRISPR Therapeutics' news discussions. The higher the estimate score, the more favorable is the investor's outlook on CRISPR Therapeutics.

CRISPR Therapeutics Implied Volatility

    
  73.67  
CRISPR Therapeutics' implied volatility exposes the market's sentiment of CRISPR Therapeutics AG stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if CRISPR Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that CRISPR Therapeutics stock will not fluctuate a lot when CRISPR Therapeutics' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards CRISPR Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, CRISPR Therapeutics' short interest history, or implied volatility extrapolated from CRISPR Therapeutics options trading.

Pair Trading with CRISPR Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CRISPR Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CRISPR Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with CRISPR Therapeutics

0.62ALXOAlx Oncology Holdings Aggressive PushPairCorr
0.81ARWRArrowhead Pharma Fiscal Year End 28th of November 2022 PairCorr

Moving against CRISPR Therapeutics

0.72ABCAmerisourcebergen Corp Fiscal Year End 3rd of November 2022 PairCorr
0.65AGTCApplied Genetic Tech Fiscal Year End 22nd of September 2022 PairCorr
0.64ACBAurora Cannabis Fiscal Year End 26th of September 2022 PairCorr
The ability to find closely correlated positions to CRISPR Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CRISPR Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CRISPR Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CRISPR Therapeutics AG to buy it.
The correlation of CRISPR Therapeutics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CRISPR Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CRISPR Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CRISPR Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to CRISPR Therapeutics Piotroski F Score and CRISPR Therapeutics Altman Z Score analysis. Note that the CRISPR Therapeutics information on this page should be used as a complementary analysis to other CRISPR Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Commodity Channel Index module to use Commodity Channel Index to analyze current equity momentum.

Complementary Tools for CRISPR Stock analysis

When running CRISPR Therapeutics price analysis, check to measure CRISPR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CRISPR Therapeutics is operating at the current time. Most of CRISPR Therapeutics' value examination focuses on studying past and present price action to predict the probability of CRISPR Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move CRISPR Therapeutics' price. Additionally, you may evaluate how the addition of CRISPR Therapeutics to your portfolios can decrease your overall portfolio volatility.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Is CRISPR Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CRISPR Therapeutics. If investors know CRISPR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CRISPR Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
B
Quarterly Revenue Growth YOY
-1.0
Return On Assets
-0.15
Return On Equity
-0.27
The market value of CRISPR Therapeutics is measured differently than its book value, which is the value of CRISPR that is recorded on the company's balance sheet. Investors also form their own opinion of CRISPR Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CRISPR Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CRISPR Therapeutics' market value can be influenced by many factors that don't directly affect CRISPR Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CRISPR Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine CRISPR Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CRISPR Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.